Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
- Campone, M.
- Im, S.-A.
- Iwata, H.
- Clemons, M.
- Ito, Y.
- Awada, A.
- Chia, S.
- Jagiełło-Gruszfeld, A.
- Pistilli, B.
- Tseng, L.-M.
- Hurvitz, S.
- Masuda, N.
- Cortés, J.
- De Laurentiis, M.
- Arteaga, C.L.
- Jiang, Z.
- Jonat, W.
- Le Mouhaër, S.
- Sankaran, B.
- Bourdeau, L.
- El-Hashimy, M.
- Sellami, D.
- Baselga, J.
ISSN: 1879-0852, 0959-8049
Ano de publicación: 2018
Volume: 103
Páxinas: 147-154
Tipo: Artigo